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Background: This interventional controlled clinical trial with split mouth design compares
the clinical effectiveness of autologous platelet rich fibrin with open flap debridement in
the management of infrabony periodontal defects.
Methods: Fifteen patients with paired contralateral infrabony defects were treated with
open flap debridement and autologous platelet rich fibrin (experimental group) or open
flap debridement alone (control group). The changes in probing pocket depth, clinical
attachment level, and radiographic defect depth were evaluated. Patient perception
regarding pain and discomfort following the procedures and early soft tissue healing
responses were assessed by visual analog scales, scored 7 days after the surgical
procedures. Final reevaluation was done 1 year after surgery.
Results: Baseline clinical and radiographic measurements were comparable between the
groups. Reevaluation at 1 year revealed that both treatment modalities resulted in a significant
decrease in probing pocket depth, gain in clinical attachment and radiographic bone fill of the
defects compared to baseline. Postoperative differences observed between the two groups
were 2.2770.29 mm (Po0.001) for probing pocket depth, 3.3370.35 mm (Po0.001) for clinical
attachment level and 1.2970.32mm (Po0.001) for radiographic infrabony defect depth
reduction, all in favor of the experimental group. Patient preference was greater and early
healing response better for the experimental group as assessed by the visual analog scores.
Conclusion: Within the limitations of this study it can be concluded that use of platelet rich
fibrin is more effective than open flap debridement alone in the management of infrabony
periodontal defects.
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The ultimate goal of periodontal therapy is the regeneration
of lost tissues. Periodontal regeneration involves the forma-
tion of alveolar bone, cementum, and a new functional
periodontal ligament [1]. For periodontal regeneration to
occur, a number of biologic events; including cell migration,
adherence, multiplication, and differentiation, need to occur
in a well-orchestrated sequence [2].
For many years, research has attempted to use biologically
active molecules to achieve periodontal regeneration. Polypep-
tide growth factors (PGFs) are biologic mediators that have the
ability to regulate cell multiplication, migration, and differentia-
tion. Several PGFs have been identified in human periodontal
tissues [3]. Of all known PGFs, platelet-derived growth factor
(PDGF) was shown to exert a favorable effect on periodontal
regeneration as measured by gain in clinical attachment and
radiographic defect fill in humans [3,4].
Though the use of growth factors has shown tremendous
promise in periodontal regenerative approaches, the routine
use of these growth factors in everyday clinical practice has
not been achieved so far. One of the major challenges
pertaining to the use of growth factors was the non-
availability of an ideal carrier [5].
Platelet-rich plasma (PRP) was first introduced as a delivery
system for growth factors in 1998 by Marx et al. [6]. Though
diverse clinical reports are available with regard to advan-
tages of adjunctive use of platelet concentrates to periodontal
surgical procedures [7,8], the most recent systematic review
and metaanalysis has concluded that platelet concentrates
may exert a positive adjunctive effect when used for the
treatment of infrabony defects [9].
A recent innovation in the field of dentistry is the develop-
ment of autologous platelet rich fibrin matrix (PRFm) as a
growth factor delivery system. Platelet rich fibrin is a second
generation platelet concentrate developed by Choukroun
et al. [10] in 2005.It is nothing but centrifuged blood without
any addition and avoids any kind of biochemical handling of
blood. The combined properties of fibrin, platelets, leuko-
cytes, growth factors and cytokines makes platelet rich fibrin
a healing biomaterial [11] with tremendous potential for bone
and soft tissue regeneration. The available data are limited,
and further investigation is required to assess the regenera-
tive potential of platelet rich fibrin, which led us to examine
the hypothesis of an enhanced regenerative outcome of
PRFm in infrabony periodontal defects.The aim of this interventional controlled clinical trial was
to assess the clinical effectiveness of PRFm to bring about
periodontal regeneration by comparing it with conventional
open flap debridement in periodontal infrabony defects. This
study also aimed to assess the patient perception and pre-
ference for these two surgical techniques considering pain and
discomfort during the first week of surgery and the differences
in early healing response by means of visual analog scales.2. Materials and methods
This controlled clinical trial with a split mouth design was
conducted in the department of Periodontics, Government
Dental College, Kozhikode, Kerala, India from September 2009
to October 2010. The study consisted of an experimental
group which was treated by placement of platelet rich fibrin
following open flap debridement (OFDþPRFm) and a control
group treated by open flap debridement (OFD) alone. Clinical
and radiographic parameters were reevaluated after 1 year.2.1. Sample size
The ideal sample size to assure adequate power for this
clinical trial was calculated as described by Chan [12]. It was
determined that 11 defects per group would be necessary to
provide 80% power with a of 0.05.
Fifteen systemically healthy, non-smoking subjects were
selected for the study. Prior to initiating this study, the
patients were informed of the purpose and design of this
clinical trial and were required to sign an informed consent.
The study design and consent form were approved by the
Institutional ethics committee, Government Dental College,
Kozhikode in accordance with the Helsinki Declaration of
1975 as revised in 2000.
The criteria for inclusion of subjects in this study were
individuals who:1. had paired, contralateral interproximal infrabony defect
with a probing pocket depth (PD) Z6 mm, clinical attach-
ment level (CAL) lossZ5 mm, and an osseous defect depth
estimated from radiographic evaluation (IBD) as Z4 mm;2. were systemically healthy without a history of allergies; and3. had at least 2 mm of keratinized gingiva on the facial
aspect of the selected tooth.
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onHematological or immunological disorders.2. Pregnancy or lactation.3. Smoking or the use of other tobacco products.4. Those taking drugs known to interfere with wound
healing.5. Had used antibiotics within the previous 1year;6. Had been treated for periodontitis during the previous 2
years.7. Those with unacceptable oral hygiene (plaque index
(PI42)) after the reevaluation of phase I therapy.8. Were not willing to sign an informed consent.
2.1.1. Presurgical therapy
Prior to the surgery, after careful instructions on proper oral
hygiene measures full mouth scaling and root planing
procedures were performed under local anesthesia. Six to
eight weeks following phase I therapy, periodontal evaluation
was performed to confirm the suitability of the sites for this
study and baseline data was recorded. The sites were divided
into experimental and control groups at the time of period-
ontal surgery. Either right sided or maxillary defects were
operated first and whether the site belonged to experimental
or control group was determined by a simple lottery method
by the toss of a coin.2.1.2. Pro forma
A detailed questionnaire was used to record demographic
data, clinical and radiographic parameters.2.1.3. Clinical parameters
A clinical examination was performed by a single examiner
(NS) who was masked to the treatment group to which a
patient was assigned, at baseline and 1 year after the surgical
procedure. The clinical parameters assessed included prob-
ing depth (PD), recession/enlargement (REC), and clinical
attachment level (CAL). Patient oral hygiene status and
gingival inflammation were evaluated using plaque index
(PI) [13] and Modified Gingival Index [14] (MGI) respectively.. 1 – Illustration showing radiographic measurements perfor
the root surface, BoBD—base of bone defect, IBD—distance f2.1.4. Radiographic examination
Standardized reproducible radiographs using paralleling cone
technique with positioning aids were taken at each experi-
mental and control site at baseline and 1 year after surgery.
All radiographs were evaluated by a single examiner (RJ) who
was masked to the treatment group to which a patient was
assigned and also to whether the radiograph was taken at
baseline or reevaluation. All radiographs were superimposed
on a standardized transparent calibration sheet and mea-
surements were made. Radiographic infrabony defect depth
(IBD) was assessed using the method described by Cardar-
opoli and Leonhard [15]. The vertical dimension between the
projection of the bone crest on the root surface (BCP) and the
most coronal level along the root surface where the period-
ontal ligament space was considered to have a normal width
(BoBD—base of bone defect) was measured and designated as
infrabony defect depth (IBD¼BCPBoBD).The distance from
the crest of remaining alveolar bone to the cementoenamel
junction (CEJ) was also recorded (CEJ-BC) (Fig. 1).
2.1.5. Treatment procedures
All periodontal surgical procedures were performed by a
single operator (AR). Standard surgical procedures for experi-
mental and control sites were performed as follows. After
local anesthesia, crevicular incisions were made and full-
thickness mucoperiosteal flaps were elevated. Vertical releas-
ing incisions were performed only if necessary for better
access or to achieve more favorable closure of the surgical
site. Meticulous defect debridement and root planing were
carried out to remove sub gingival plaque, calculus, inflam-
matory granulation tissue, and pocket epithelium.
2.1.6. Preparation of platelet rich fibrin matrix (PRFm)
10 ml blood was drawn by venipuncture of the right ante-
cubital vein. Blood was collected in sterile glass test tubes
without any anticoagulants and immediately centrifuged on
a table top centrifuge (KW-70, AlmicroTM Instruments,
Ambala Cantt., Haryana, India) at 3000 rpm for 10 min. This
resulted in the separation of three basic fractions because of
differential densities: the bottom red blood cells (RBCs),
middle platelet rich fibrin (PRFm), and the top layer of
platelet-poor plasma (PPP). PPP was aspirated and discarded
and the PRFm was separated from underlying RBC s by themed. BC—bone crest level. BCP—projection of the bone crest
rom BCP to BoBD.
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diately placed into the infrabony osseous defects in the
experimental group. Surgical flaps were repositioned to their
presurgical level and sutured with 4-0 silk sutures achieving
primary closure. Periodontal packs were placed to cover the
surgical areas. Control sites were treated in every way similar
to experimental sites except for the preparation and place-
ment of PRFm.2.1.7. Postsurgical care
Postoperative care included systemic administration of
amoxicillin, 500 mg, every 8 h for 5 days, paracetamol
500 mg every 8 h for 3 days and 0.2% chlorhexidine digluco-
nate rinse three times daily for 6 weeks. Sutures were
removed 1 week post-surgery .
A visual analog scale (VAS1) was used to assess the patient
experience with the two treatment modalities. At 1 week after
the procedure the patient was asked to assign scores for the
surgical procedure with a minimum score of 0 and a maximum
score of 10 taking into consideration: (1) pain during the first
week after surgery and duration for which the pain lasted; (2)
redness and discomfort during the first week after surgery; and
(3) overall perception of the surgical procedure and patient
opinion regarding the procedure. Study subjects assigned max-
imum scores to the surgical procedure of their preference. Thus
higher scores indicated higher patient acceptance and mini-
mum immediate post-operative discomforts.
Another visual analog scale (VAS2) was designed and used
to assess the initial soft tissue healing which was done by an
examiner who was unaware of the group to which the patient
belonged. Scoring was done based on the early changesTable 1 – Comparison of baseline clinical and radio-
graphic parameters (Mann–Whitney test).
Parameter Experimental
group
(mean7SD)
Control
group
(mean7SD)
P
value
PD (mm) 7.5371.06 7.0771.03 0.23
CAL (mm) 8.2071.21 7.5371.30 0.16
REC (mm) 0.6770.98 0.3370.62 0.27
CEJ-BC (mm) 1.5071.16 1.2171.05 0.50
IBD (mm) 5.0771.08 4.5770.65 0.15
Table 2 – Changes in clinical and radiographic parameters fro
Parameter Experimental group
Baseline Reevaluation
(1 year)
P
Val
(mean7SD)
PD (mm) 7.5371.06 2.8770.99 0.0
CAL (mm) 8.2071.21 3.4771.45 0.0
REC (mm) 0.6770.98 0.6070.83 0.3
CEJ-BC (mm) 1.5071.16 1.4371.22 0.6
IBD (mm) 5.0771.08 3.1471.35 0.0healing of the surgical site. The scoring criteria were:1-m
ue
01
01
17
55
01Mild inflammation (slight change in color/texture) of any
unit of gingiva.2- Mild inflammation of the entire gingival unit.3- Moderate inflammation (moderate glazing, redness,
edema, and/or enlargement) of the gingival unit.4- Severe inflammations (redness, edema, enlargement,
spontaneous bleeding or ulceration) of the gingival unit.
2.1.8. Maintenance phase
After suture removal, mechanical plaque control using the
roll tooth brushing technique was resumed at the surgically
treated sites. The patients were recalled once a month up to 1
year post-surgery for oral hygiene reinforcement and pro-
phylaxis. All clinical and radiographic measurements were
rerecorded at the end of 1 year.
2.2. Statistical analysis
All data were analyzed using statistical software (SPSS 17.0 for
Windows, SPSS South Asia (P) Limited, Bangalore, India). Results
were averaged (mean7SD) for probing pocket depth, clinical
attachment level, gingival recession, Infrabony defect depth,
and alveolar crest resorption. The net difference between each
pair of measurements (pre- and postoperative) was calculated,
followed by computation of the difference between treatment
groups. Wilcoxon Signed Ranks Test was used to compare
means between baseline and 1 year in each of the groups.
Mann–Whitney test was used for intergroup comparisons at
baseline and after 1 year.
For the visual analog scores, the frequency with which each
score occurred was recorded for the experimental and control
groups. Intra- and intergroup comparisons were made using the
w2 test.3. Observations and results
The study group consisted of 15 patients with a mean age of
29.4777.65 years (range 17–44 years). There were 9 female and
6 male patients in the study group. The mean plaque index
scores at baseline was 1.2470.25 and the mean modified
gingival index scores were 1.2770.34. Proper oral hygiene
maintenance was ensured throughout the maintenance
phase. All 15 patients completed the study. Defects in thebaseline to reevaluation (Wilcoxon signed ranks test).
Control group
Baseline Reevaluation
(1 year)
P
Value
(mean7SD)
7.0771.03 4.6770.82 0.000
7.5371.30 6.1371.46 0.002
0.3370.62 1.4771.13 0.002
1.2171.05 1.3671.22 0.317
4.5770.646 3.9370.83 0.003
Table 3 – Comparison of Mean changes obtained for clinical and radiographic parameters between the two groups at
reevaluation (Mann–Whitney test).
Parameter Experimental Control change between groups P value
(Mean7SD) (Mean7SD) (Mean7SE)
PD change (mm) 4.6770.90 2.4070.63 2.2770.29 0.000
CAL change (mm) 4.7370.88 1.4071.06 3.3370.35 0.000
REC change (mm) 0.0770.26 1.1370.74 1.2070.20 0.000
CEJ-BC change (mm) 0.0770.62 0.1470.54 0.2170.21 0.541
IBD change (mm) 1.9371.07 0.6470.50 1.2970.32 0.001
Table 4 – Patient perception and acceptance between the
two groups (VAS1).
Count Group P value
Experimental Control
4 0 3 0.024
5 1 4
6 4 6
7 6 2
8 4 0
Total 15 15
Table 5 – Assessment of early healing response (VAS2).
Count Group P-value
Experimental Control
1 5 0 0.036
2 7 8
3 3 7
Total 15 15
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cases of flap dehiscence or infection were detected.
Both groups were comparable at baseline with respect to
probing depth (PD), clinical attachment level (CAL), gingival
recession (REC) depth of the infrabony defects (IBD) and
distance from the cementoenamel junction to bone crest(-
CEJ-BC) (Table 1).
Both the experimental group and the control group showed
a significant gain in clinical attachment levels and probing
depth reduction and reduction in infrabony defect depth at 1
year (Table 2). There was no significant gingival recession in
the experimental group during the 1 year after the surgery.
However there was a statistically significant gingival reces-
sion with a mean value of 1.1370.74 mm in the control group
during the same time interval (Table 2).
Though both groups achieved statistically significant
improvements in the clinical and radiographic parameters
assessed it was found that the magnitude of improvements
in these parameters were significantly higher for the experi-
mental group (Table 3).
Experimental sites presented with greater mean clinical
attachment gain with a mean difference of 3.3670.38 mmbetween the groups (Po0.000). The postoperative differences
in probing depth between the two groups were found to be
2.2970.3 mm(Po0.000) in favor of the experimental sites
(Table 3). There, was a statistically significant difference of
1.270.2 mm in levels of gingival recession between the two
groups indicating a lesser mean gingival recession in the
experimental group (Table 3).
Experimental sites presented with a greater amount of
reduction in infrabony defect depth with a mean difference
in reduction of 1.2970.32 mm (Po0.000) (Table 4). There was
no significant crestal bone resorption (CEJ-BC) in either of the
groups (P¼0.541) (Table 3).
ForVAS1, in the experimental group the most commonly
recorded scores were 7 and 8 (55%). In the control group
scores 6 and 5 (67%) were most common. This difference in
frequency of scores was found to be statistically significant
between the groups (Table 4).
In VAS2 assessing the early healing soft tissue changes;
in the experimental group the score 1 (33%) and score 2
(47%) were most common. In the control group there was
no site with a score of 1. Scores 2 (53%) and 3 (47%) were
most often recorded. There was a statistically significant
difference in the frequency of scores between these two
groups (Table 5).4. Discussion
For the study, 30 infrabony sites in 15 patients were selected
using a split-mouth design. Though recent evidences suggest
both parallel and split mouth designs to be equally effective
[9], the split mouth design was chosen as this permits better
assessment of how the same host responds to two different
treatment modalities.
The sample size was enough to ensure 80% power for the
study. The sample size selected for this study was compar-
able to other interventional clinical trials in periodontal
literature. Randomization was not attempted in this clinical
trial because in split mouth design when one site was
randomly assigned as either experimental or control the
other site automatically selected itself to the remaining
group. True randomization was hence possible for only for
half the sites.
Patient blinding regarding the type of therapy was not
possible in this trial because of the procedures of blood
collection and preparation of platelet rich fibrin associated
with the experimental sites. However the investigators
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masked of the treatment group as to which the study site
belongs.
Platelet rich fibrin alone was used in the experimental
group and not as an adjunct to other regenerative approaches
like bone replacement grafts or guided tissue regeneration in
the present study. There has been conflicting reports regard-
ing the use of platelet concentrates along with bone replace-
ment grafts. Even though some studies claim a superior
clinical effectiveness for the combination [16], reports claim-
ing no added advantages for the combination are also avail-
able [17]. The recent metaanalysis [9] states that combination
of platelet concentrate with guided tissue regeneration (GTR)
masks the true effectiveness of platelet concentrates.
In the present study platelet rich fibrin was used rather
than the more extensively studied platelet rich plasma as it
offers several advantages like ease of preparation, no bio-
chemical handling of blood or use of any gelling agent like
calcium chloride and no risks associated with the use of
bovine thrombin. As it is a completely autologous material it
is highly cost effective.
The success of this technique entirely depends on the speed of
blood collection and immediate centrifugation [10]. In order to
obtain a clinically usable platelet rich fibrin clot, in the present
study a chair side centrifuge was used and it was ensured that
the freshly drawn blood was immediately transferred to the
centrifuge without any delay to prevent dehydration.
The results of this clinical trial indicate a positive effect for
the use of platelet rich fibrin in the management of infrabony
periodontal defects in terms of improvement in clinical and
radiographic parameters.
At reevaluation one interesting finding in the present study
was the absence of post-operative increase in gingival reces-
sion in the experimental group as compared to controls.
Moreover the experimental group shows a mild decrease in
preoperative recession levels (0.0770.62 mm). Even though
this value is of no clinical significance; this calls for more
clinical studies using platelet rich fibrin in the management
of gingival recession.
The improvement in clinical parameters and better bone fill
in the experimental group are suggestive of the effectiveness
of platelet rich fibrin in regenerative periodontal therapy.
These results may be attributed to the contents of the platelet
rich fibrin clot namely fibrin, platelets, leukocytes, growth
factors and cytokines.
The fibrin matrix supporting the PRFm clot constitutes
the determining element responsible for the therapeutic
potential of platelet rich fibrin [11]. The fibrin matrix plays
important role in four highly specific aspects of healing:
angiogenesis, immune control, harnessing the circulating
stem cells, and wound protection by epithelial cover
[11].
The angiogenesis property of fibrin matrix is explained by
the 3-dimensional structure of the fibrin gel and by the
simultaneous action of cytokines trapped in the meshes.
During hemostasis and healing, the fibrin clot traps the
circulating stem cells and allows the vascular and tissue
restoration. An important phase of angiogenesis is avb3
integrin expression by endothelial cells, allowing the cells
to bind to fibrin, fibronectin, and vitronectin. Regulationof this integrin expression could be brought on by fibrin
itself [18].
Among the growth factors contained in the platelet rich
fibrin clot, platelet-derived growth factors (PDGF), Insulin-like
growth factors (IGF) and transforming growth factor b (TGF-b)
play the most important roles. PDGF-a and -b receptors are
expressed in regenerating periodontal soft and hard tissues.
PDGF initiates periodontal ligament cell chemotaxis, mito-
genesis and matrix synthesis. Application of PDGF alone or in
combination with IGF-1 results in partial repair of periodontal
tissues [19].
In the present study we observed a significant bone fill in the
experimental group. Direct interactions between fibrin and
osseous cells during healing are insufficiently documented [11].
On the other hand, numerous animal studies deal with the fibrin
effect on osseous healing. The results are contradictory; osseous
healing is either improved or remains unchanged [20]. Growth
factors contained in the platelet rich fibrin clot could have
contributed to the radiographic bone fill observed in the present
study. PDGF has been shown to have a significant regenerative
impact on PDL cells and osteoblasts [21]. It has also been
reported that PRFm induces a significant and continuous stimu-
lation of proliferation in all cell types of the periodontium except
epithelial cells [22]. PRFm stimulates human bone mesenchymal
cell proliferation and differentiation [23].
Our results in the experimental group were compared to
those studies using platelet rich plasma alone as periodontal
regenerative approach [16,17]. Our results are in accordance
with these studies in terms of changes in clinical attachment
levels, probing depths, and radiographic bone fill. However
the magnitude of change in CAL and PD at reevaluation is
much higher in the present study as compared to studies
using PRP alone.
It has been reported that the CAL gain after conventional or
regenerative periodontal treatment was dependent on the
initial PD; that is, deeper the initial PD, the greater the PD
reduction and the CAL gain [24]. This is significant consider-
ing that the baseline levels of probing pocket depth and
Clinical attachment levels in the present study were compar-
able to studies that used PRP [16,17]. Markou et al. [17]
reported a mean improvement in PD of 3.9271.1 mm, CAL
of 3.0870.95 mm 1 year after periodontal surgery. Tunc Ilgenli
et al. [16] reported a mean improvement in PD of 2.170.5 mm,
CAL of 1.570.7 mm and a radiographic reduction of infrabony
defect depth of 0.671.2 mm 18 months after surgery. In
contrast, the present study reports a mean change in PD of
4.6770.90 mm, CAL of 4.7370.88 mm and a radiographic
reduction in infrabony defect depth of 1.9371.07 mm at 1
year after surgery.
The reason for the improved results with platelet rich fibrin
may be attributed to the difference in structure between PRP
and PRFm [10] and their growth factor content. PRP uses a
bovine thrombin and calcium chloride resulting in sudden
fibrin polymerization. PRFm has the characteristic of poly-
merizing naturally and slowly under physiologic concentra-
tions of autologous thrombin. This difference in polymeriza-
tion results in two different biochemical architectures for the
resulting product: Condensed tetra molecular or bilateral
junctions in PRP and connected trimolecular or equilateral
junctions in PRFm [25].
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concentrations and allow the thickening of fibrin polymers;
this leads to the constitution of a rigid network, not very
favorable to cytokine enmeshment and cellular migration. In
contrast equilateral junctions allow the establishment of a
fine and flexible fibrin network able to support cytokines
enmeshment and cellular migration. Moreover, this 3-
dimensional organization will give great elasticity to the
fibrin matrix.
There are wide variations in quantity of growth factor
released from platelet concentrates prepared using different
preparation protocols. A study by Gassling [26] assessed
Growth factor release from PRP and platelet rich fibrin (PRF)
and found that after 10 days the amount of growth factors
released from PRP is higher than that from PRF. However in a
comparative study He et al. [27] concluded that PRF released
autologous growth factors gradually and expressed stronger
and more durable effect on proliferation and differentiation
of rat osteoblasts than PRP in vitro.
Our study also evaluated the patient perception with
respect to the two surgical procedures using a visual analog
scale. Majority of patients reported a preference for regen-
erative surgery with PRFm. It has been proposed that PRFm is
a healing biomaterial that accelerates wound closure and
mucosal healing, with a significant diminution of pain and
discomfort, due to fibrin bandage and growth factor release
[11]. However a Hawthorne effect could have also played a
part in these results as the patient could not be blinded to the
procedures.
A second visual analog scale was used to assess the early
wound healing. The experimental group had significantly
lower scores indicating that PRFm indeed accelerates early
wound healing. Degranulation of leukocytes in the PRFm
could release cytokines into the fibrin clot. The major cyto-
kines reported to be present in PRFm are proinflammatory
cytokines like interleukin 1 b (IL1 b), interleukin 6(IL 6), tumor
necrosis factor a (TNF a) and anti-inflammatory cytokines
interleukin 4(IL 4). SoPRFm clot could be considered as an
immune organizing node and its defense capacities against
infections would be quite significant [28]. This could have
contributed to the better healing responses and enhanced
patient comfort.
Whether the damaged tissues heal by regeneration or
repair following any periodontal regenerative approach
depends upon two crucial factors: the availability of cell
type(s) needed; and the presence or absence of cues and
signals necessary to recruit and stimulate these cells [29]. The
use of platelet rich fibrin provides a convenient approach by
which the presence of both these factors can be expected at
the surgical sites. Thus the added advantages of fibrin and
the sustained release of growth factors present in the platelet
rich fibrin matrix could be responsible for the superior results
observed in the experimental group of our study. Future
researches focusing on clinical trials and histological evalua-
tions are necessary to further assess the periodontal regen-
erative potential of platelet rich fibrin.
The limitations associated with this controlled interven-
tional clinical trial are the inability to do true randomization
and assessment of periodontal regeneration through assess-
ment of clinical and radiographic parameters alone.5. Conclusions
Within the limitations of this study it can be concluded:1. Use of platelet rich fibrin significantly improved the
clinical and radiographic parameters that were assessed
in this study.2. Platelet rich fibrin significantly reduced the postoperative
pain and discomfort after periodontal surgery and signifi-
cantly accelerated periodontal wound healing.It remains to be seen whether the adjunctive use of other
regenerative approaches along with platelet rich fibrinincreases its clinical effectiveness or masks its true regen-
erative potential. Multicenter trials with large sample size
and longer follow up time are required to further assess the
regenerative potential of platelet rich fibrin.
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